In the Rare Oncology Agnostic Research (ROAR) basket trial, combination therapy with dabrafenib and trametinib shows good efficacy against biliary tract cancer cases with BRAF V600 mutations, an investigator-assessed overall response of 51%, and an independent reviewer-assessed overall response of 47%. This evidence concerns the gene BRAF and biliary tract cancer.